Edition:
United States

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

4.10USD
28 Apr 2017
Change (% chg)

$-0.30 (-6.82%)
Prev Close
$4.40
Open
$4.40
Day's High
$4.40
Day's Low
$4.00
Volume
74,116
Avg. Vol
64,153
52-wk High
$5.25
52-wk Low
$1.10

CGIX.OQ

Chart for CGIX.OQ

About

Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $81.02
Shares Outstanding(Mil.): 19.76
Dividend: --
Yield (%): --

Financials

  CGIX.OQ Industry Sector
P/E (TTM): -- 32.85 30.08
EPS (TTM): -1.04 -- --
ROI: -44.89 5.55 13.25
ROE: -53.90 8.65 14.41

BRIEF-Cancer Genetics and Mendel.ai announce strategic partnership

* Cancer Genetics, Inc. and Mendel.ai announce strategic partnership enabling artificial intelligence in precision medicine to drive personalized treatment and accelerate clinical trial matching for cancer care

Apr 03 2017

BRIEF-Cancer Genetic Q4 loss per share $0.15

* Cancer Genetics, Inc. Announces record revenue for fourth quarter and full-year 2016 and provides 2017 business update

Mar 23 2017

BRIEF-Cancer Genetics says received approval for a $1 mln gross tax credit from New Jersey technology business tax certificate transfer program

* Cancer Genetics Inc - received approval for a $1.0 million gross tax credit from New Jersey technology business tax certificate transfer program Source text for Eikon: Further company coverage:

Feb 22 2017

BRIEF-CANCER GENETICS LAUNCHES FOCUSED GENOMIC PANEL FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME

* HAS LAUNCHED A FOCUSED GENOMIC PANEL FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME (HBOC)

Jan 25 2017

BRIEF-Cancer Genetics announced strategic collaboration with Lantern Pharma

* Announced a strategic collaboration with lantern pharma, inc

Jan 17 2017

BRIEF-Cancer Genetics announces agreements to develop liquid biopsy programs

* Cancer genetics, inc. Announces multiple agreements & collaborations to develop liquid biopsy programs with leading biopharma companies

Jan 09 2017

BRIEF-Cancer Genetics Q3 loss per share $0.23

* Q3 revenue $6.8 million Source text for Eikon: Further company coverage:

Nov 10 2016

More From Around the Web

Competitors

Earnings vs. Estimates